Apogenix To Present At Three Upcoming International Conferences
HEIDELBERG, Germany, Oct. 13, 2015 /PRNewswire/ -- Apogenix, a next generation immuno-oncology company, announced today that Chief Executive Officer Thomas Hoeger, Ph.D., will present at the BIO Investor Forum, the Sofinnova Japan Biopharma Partnering Conference, and the German Equity Forum.
BIO Investor Forum
Venue: Parc 55, San Francisco, CA, USA
Presentation: October 20, 2015, 8:30 a.m. PDT, Room Davidson
Sofinnova Japan Biopharma Partnering Conference
Venue: Conrad Hotel, Tokyo, Japan
Presentation: October 27, 2015, 8:45 a.m. JST, Room Nagisa
German Equity Forum
Venue: Sheraton Frankfurt Airport Hotel & Conference Center, Frankfurt am Main, Germany
Presentation: November 25, 2015, 10:30 a.m. CEST, Room Oslo
About Apogenix
Apogenix develops innovative immuno-oncology therapeutics for the treatment of cancer and other malignant diseases. The company has built a promising pipeline of drug candidates that target different tumor necrosis factor superfamily (TNFSF)-dependent signaling pathways, thereby restoring the immune response against tumors. Since its inception in fall 2005, Apogenix has raised more than 50 million euros from its investors and received public grants and upfront payments from licensing agreements totaling more than 20 million euros. The company is based in Heidelberg, Germany.
Contact | |
Thomas Hoeger, Ph.D., CEO | |
Apogenix GmbH | |
Phone: +49 (6221) 58 60 80 | |
E-Mail: contact@apogenix.com | |
Web: www.apogenix.com | |
Media Contacts | |
USA: | Europe: |
Matt Middleman, M.D. | Raimund Gabriel |
Russo Partners, LLC | MC Services AG |
Phone: +1 (212) 845 4272 | Phone: +49 (89) 210 228 30 |
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/apogenix-to-present-at-three-upcoming-international-conferences-300158493.html
SOURCE Apogenix
Help employers find you! Check out all the jobs and post your resume.